The biotechnology sector is currently at a strategic crossroads, marked by the increasing integration of artificial intelligence (AI) and the challenges posed by the "patent cliff." The latter, representing a potential loss of $400 billion, compels companies to innovate rapidly to offset the loss of patents. AI, as an innovation catalyst, plays a crucial role in drug discovery and the optimization of research and development (R&D) processes. Recent advances, such as the AI simulation of 500 million years of evolution to discover an artificial fluorescent protein, illustrate the transformative potential of these technologies.